Synergistic Effects of Gentamicin, Cefepime, and Ciprofloxacin on Biofilm of Pseudomonas aeruginosa

References

• Barbier M, Owings JP, Martínez-Ramos I, et al. Lysine trimethylation of EF-Tu mimics platelet-activating factor to initiate Pseudomonas aeruginosa pneumonia. MBio. 2013;4(3):e00207–13. doi:10.1128/mBio.00207-13
   PubMed Web of Science ®Google Scholar
• Fazzeli H, Akbari R, Moghim S, Narimani T. Pseudomonas aeruginosa infections in patients, hospital means, and personnel’s specimens. Univ Med Sci. 2012;17(7):671–675.
   Google Scholar
• Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, van Duin D. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria. Antimicrob Agents Chemother. 2017;61(6):e02671–16. doi:10.1128/AAC.02671-16
   PubMed Web of Science ®Google Scholar
• Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care. 2015;19:1–8. doi:10.1186/s13054-015-0926-5
   PubMed Web of Science ®Google Scholar
• Tamma P, Aitken S. Bonomo R IDSA guidance on the treatment of antimicrobial-resistant gram-negative infections: version 1.0. IDSA. 2022.
   Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803. doi:10.1093/cid/ciy378
   PubMed Web of Science ®Google Scholar
• Al Salman J, Al Dabal L, Bassetti M, et al. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. Int J Antimicrob Agents. 2020;56(4):106104. doi:10.1016/j.ijantimicag.2020.106104
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Sobrevivir Sepsis Campaign: directrices internacionales para el manejo de la sepsis y el shock séptico: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs in Context. 2018;7:1–18. doi:10.7573/dic.212527
   Google Scholar
• Bassetti M, Vena A, Russo A, Croxatto A, Calandra T, Guery B. Rational approach in the management of Pseudomonas aeruginosa infections. Curr Opin Infect Dis. 2018;31(6):578–586. doi:10.1097/QCO.0000000000000505
   PubMed Web of Science ®Google Scholar
• Zakhour J, Sharara SL, Hindy J-R, Haddad SF, Kanj SS. Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis. Antibiotics. 2022;11(10):1432. doi:10.3390/antibiotics11101432
   Google Scholar
• Burgess DS, Nathisuwan S. Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2002;44(1):35–41. doi:10.1016/S0732-8893(02)00420-0
   PubMed Web of Science ®Google Scholar
• Macia M, Rojo-Molinero E, Oliver A. Antimicrobial susceptibility testing in biofilm-growing bacteria. Clin Microbiol Infection. 2014;20(10):981–990. doi:10.1111/1469-0691.12651
   PubMed Web of Science ®Google Scholar
• Noreen A, Masood H, Zaib J, et al. Investigating the Role of Antibiotics on Induction, Inhibition and Eradication of Biofilms of Poultry Associated Escherichia coli Isolated from Retail Chicken Meat. Antibiotics. 2022;11(11):1663. doi:10.3390/antibiotics11111663
   Google Scholar
• Nucleo E, Steffanoni L, Fugazza G, et al. Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol. 2009;9(1):1–14. doi:10.1186/1471-2180-9-270
   PubMedGoogle Scholar
• Clinical and Laboratory Standard Institute (CLSI). M100 Performance Standards for Antimicrobial Susceptibility Testing 30th ed.; An Informational Supplement; CLSI: Wayne, PA, USA; 2020. Available from: https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf. Accessed August 27, 2023.
   Google Scholar
• Jarlier V, Nicolas M-H, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Clin Infect Dis. 1988;10(4):867–878. doi:10.1093/clinids/10.4.867
   Google Scholar
• Anderson K, Lonsway D, Rasheed J, et al. Evaluation of Methods to Identify the Klebsiella pneumoniae in. J Clin Microbiol. 2007;45(8):2723–2725. doi:10.1128/JCM.00015-07
   PubMed Web of Science ®Google Scholar
• Ali I, Rafaque Z, Ahmed I, et al. Phylogeny, sequence-typing and virulence profile of uropathogenic Escherichia coli (UPEC) strains from Pakistan. BMC Infect Dis. 2019;19(1):1–9. doi:10.1186/s12879-019-4258-y
   PubMedGoogle Scholar
• Rafaque Z, Abid N, Liaqat N, et al. In-vitro investigation of antibiotics efficacy against uropathogenic Escherichia coli biofilms and antibiotic induced biofilm formation at sub-minimum inhibitory concentration of ciprofloxacin. Infect Drug Resist;2020. 2801–2810. doi:10.2147/IDR.S258355
   PubMed Web of Science ®Google Scholar
• Drago L, De Vecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy. 2004;50(4):202–210. doi:10.1159/000081033
   PubMed Web of Science ®Google Scholar
• Thiyagarajan D, Das G, Ramesh A. Amphiphilic Cargo‐Loaded Nanocarrier Enhances Antibiotic Uptake and Perturbs Efflux: effective Synergy for Mitigation of Methicillin‐Resistant Staphylococcus aureus. ChemMedChem. 2017;12(14):1125–1132. doi:10.1002/cmdc.201700260
   PubMed Web of Science ®Google Scholar
• Wang L, Di Luca M, Tkhilaishvili T, Trampuz A, Gonzalez Moreno M. Synergistic activity of fosfomycin, ciprofloxacin, and gentamicin against Escherichia coli and Pseudomonas aeruginosa biofilms. Front Microbiol. 2019;10:2522. doi:10.3389/fmicb.2019.02522
   PubMed Web of Science ®Google Scholar
• Dosler S, Karaaslan E, Alev Gerceker A. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28(2):95–103. doi:10.1179/1973947815Y.0000000004
   PubMed Web of Science ®Google Scholar
• Almaaytah A, Abualhaijaa A, Alqudah O. The evaluation of the synergistic antimicrobial and antibiofilm activity of AamAP1-Lysine with conventional antibiotics against representative resistant strains of both Gram-positive and Gram-negative bacteria. Infect Drug Resist. 2019;1371–1380. doi:10.2147/IDR.S204626
   PubMed Web of Science ®Google Scholar
• Ghorbani H, Memar MY, Sefidan FY, Yekani M, Ghotaslou R. In vitro synergy of antibiotic combinations against planktonic and biofilm Pseudomonas aeruginosa. GMS Hygiene Infection Control. 2017;12. doi:10.3205/dgkh000302
   PubMedGoogle Scholar
• Gupta P, Chhibber S, Harjai K. Subinhibitory concentration of ciprofloxacin targets quorum sensing system of Pseudomonas aeruginosa causing inhibition of biofilm formation & reduction of virulence. Indian J Med Res. 2016;143(5):643. doi:10.4103/0971-5916.187114
   PubMedGoogle Scholar
• Ellappan K, Narasimha HB, Kumar S. Coexistence of multidrug resistance mechanisms and virulence genes in carbapenem-resistant Pseudomonas aeruginosa strains from a tertiary care hospital in South India. J Global Antimicrobial Resistance. 2018;12:37–43. doi:10.1016/j.jgar.2017.08.018
   PubMed Web of Science ®Google Scholar
• Ullah W, Qasim M, Rahman H, et al. Multi drug resistant Pseudomonas aeruginosa: pathogen burden and associated antibiogram in a tertiary care hospital of Pakistan. Microb Pathog. 2016;97:209–212. doi:10.1016/j.micpath.2016.06.017
   PubMed Web of Science ®Google Scholar
• Gimeno C, Cantón R, García A, Gobernado M. Comparative activity of doripenem, meropenem, and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study. Revista Espanola de Quimioterapia. 2010;23(3):144–152.
   PubMed Web of Science ®Google Scholar
• Shenkutie AM, Zhang J, Yao M, Asrat D, Chow FW, Leung PH. Effects of sub-minimum inhibitory concentrations of imipenem and colistin on expression of biofilm-specific antibiotic resistance and virulence genes in Acinetobacter baumannii sequence type 1894. Int J Mol Sci. 2022;23(20):12705. doi:10.3390/ijms232012705
   PubMed Web of Science ®Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infection. 2022;28(4):521–547. doi:10.1016/j.cmi.2021.11.025
   PubMed Web of Science ®Google Scholar
• Anderl JN, Franklin MJ, Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2000;44(7):1818–1824. doi:10.1128/AAC.44.7.1818-1824.2000
   PubMed Web of Science ®Google Scholar
• Vrany JD, Stewart PS, Suci PA. Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa biofilms displaying rapid-transport characteristics. Antimicrob Agents Chemother. 1997;41(6):1352–1358. doi:10.1128/AAC.41.6.1352
   PubMed Web of Science ®Google Scholar